Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H5N8 Vaccine Mix and Match with AS03 or MF59
NCT03014310Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Influenza A (H5N8) Monovalent Vaccine in Avian Influenza (AI) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titers of Neut antibodies against the A/H5N8 antigen at Day 43, Geometric Mean Titers of serum HAI antibodies against the A/H5N8 antigen at Day 43 and 5 more. Started Jan 2017; status: completed.
02
Drugs
Influenza A (H5N8) Monovalent Vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03014310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014310.